Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Recent advances in CAR-MSCs: the new engine of cellular immunotherapy evolution

Chen Y., Li J., Ma Y., Fang J., Yang Y., Yan L.

Narrative Review on Immune Modulation, published in J Hematol Oncol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Hematol Oncol (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41146171
PMCID
PMC12557984
DOI
10.1186/s13045-025-01746-7
Citations
5

Abstract (original English)

In recent years, the development of chimeric antigen receptor (CAR) technology has greatly promoted the progress of cellular immunotherapy. Among them, CAR-T cell therapy has shown remarkable clinical effects in the treatment of hematological malignancies. However, this therapy still faces a series of challenges, including immunogenicity, toxic side effects, and insufficient maintenance of long-term efficacy. The latest research progress has extended CAR technology to mesenchymal stem cells (MSCs), and the resulting CAR-MSCs combine the precise targeting ability of CAR molecules with the inherent immunomodulatory, tissue homing, and regenerative repair properties of MSCs, providing a new therapeutic strategy for cancer and immune-related diseases. This review examines the engineering design, biological characteristics, and applications of CAR-MSCs in oncology and immune-related disorder therapy. Preclinical studies have shown their effectiveness against glioblastoma, Ewing sarcoma, acute myeloid leukemia, and lung cancer, as well as graft-versus-host disease, through TRAIL secretion, bispecific antibody production, and Treg induction. Despite promising results, significant hurdles persist in CAR-MSC manufacturing scalability, cell persistence, heterogeneous MSC tissue sourcing, and undefined application protocols, all of which are critical for clinical translation. We investiga

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Mesenchymal Stem CellsAnimalsHumansNeoplasmsImmunotherapy, AdoptiveMesenchymal Stem Cell TransplantationReceptors, Chimeric Antigen

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research